---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-029561"
form_type: "8-K/A"
ticker: "AVTX"
cik: "0001534120"
company_name: "Avalo Therapeutics, Inc."
filed_at: "2024-06-24T23:59:59+00:00"
generated_at: "2026-06-01T02:26:27.727498+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Avalo amends 8K to restate AlmataBio 2023 financials; net loss up $153K

## Summary
- Restated AlmataBio net loss for April 28–Dec 31, 2023 to $812K from $659K, a $153K increase.
- R&D expense corrected upward by $135K to $663K; G&A expense up $18K to $149K.
- Restatement had no cash flow impact; cash and equivalents remained $1.767M at Dec 31, 2023.
- Previously issued financials for AlmataBio are superseded by this restated filing.
- Acquisition of AlmataBio by Avalo closed on March 27, 2024; this is Amendment No. 2 to the original 8-K.

## SEC filing metadata
- accession: 0001628280-24-029561
- form_type: 8-K/A
- ticker: AVTX
- cik: 0001534120
- company_name: Avalo Therapeutics, Inc.
- filed_at: 2024-06-24T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534120/000162828024029561/0001628280-24-029561-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534120/000162828024029561/avtx-20240327.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-029561
- JSON: https://secwatch.observer/filing/0001628280-24-029561.json
- Plain text: https://secwatch.observer/filing/0001628280-24-029561.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.